Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor.

In this study, the performance of the commercially available LymphoTrack high-throughput sequencing assay was assessed for determining residual disease burden in patients with various T-cell malignancies seen at our institution.

Source: Journal of Molecular Diagnostics - March 2, 2023 Category: Pathology Authors: Jack K. Tung, Diwash Jangam, Chandler C. Ho, Eula Fung, Michael S Khodadoust, Youn H. Kim, James L. Zehnder, Henning Stehr, Bing M. Zhang Tags: Regular Article Source Type: research